In preparation for fund raising and collaborator meetings in the US, VaccineTab required market evaluation, competitor landscaping and the development of the Unique Value Proposition (UVP) of the VaccineTab technology. NanoScientium delivered all of the above in a very short time frame, as well as recommendations for funding/investment streams and key potential partners to engage in the US.
Dr Claire Thompson, Director of NanoScientium said “We are delighted to work with such an exciting start-up. Dr Kett and her team have developed a novel, thermally stable vaccine delivery system with multiple applications across human and animal markets. We look forward to seeing the company advance and working with them again in the future”.
Dr Vicky Kett, Founder and Director of Vaccine Tab commented “The Nanoscientium team were efficient, adaptable and professional throughout. We were delighted with the quality of their service and of the report that was produced and would not hesitate to use them again. ”
NanoScientium fast-tracks nanotechnologies into products and profits in the healthcare sector. We enable our Clients’ route to market strategy, including clinical and regulatory pathways, illustrate their position in the competitive landscape and value their market(s). They convert evidence into business intelligence to enable the development, investment and acquisition strategies for Clients such as:
• Nanotechnology Researchers/Developers
• Pharmaceutical and Medical Device companies
Their Management Team of Senior Executives has over 25 years of expertise in nanotechnology, medicine and device development and business analytics. These complimentary skills enable NanoScientium to deliver optimal strategic value for their Clients.
For further information on NanoScientium, please contact email@example.com
About Vaccine Tab
VaccineTab was founded in August 2014 as a start-up from Queen’s University Belfast. The company’s mission is to revolutionise the global vaccine market through their unique nasal delivery technology that offers improved thermal stability. The technology comprises a proprietary liposome incorporated into a solid tablet suitable for administration of vaccine intranasally and via other routes.
For further information on VaccineTab, please contact firstname.lastname@example.org